FIRE Funds Income Target ETF FIRI 深 滬
等待開盤 12-12 09:30:00 美东时间
18.9449
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 總市值 123.14万
- 52周最高 19.115
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 總股本 6.50万
- 歷史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 歷史最低 17.7417
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akari Therapeutics Reports Its AKTX-101 Shows Potent Preclinical Activity Against K-Ras G12V Pancreatic Cancer Cells
Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival
12-09 21:41
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.
10-24 15:05
Inhibrx Biosciences To Webcast ChonDRAgon Study Results For Ozekibart In Chondrosarcoma On October 23
– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical
10-23 04:02
Merus Reports Interim Phase 2 Results for Petosemtamab in Metastatic Colorectal Cancer
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and
10-14 19:34
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
09-29 20:19
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-16 19:00
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Break...
09-08 21:30
Oncolytics Biotech Reports Pelareorep Boosts Survival In Colorectal Cancer Patients
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today highlighted clinical and translational data from three metastatic
09-08 19:10
AIM ImmunoTech Announces Company Update Including Mid-Year Report Of Ampligen In Combination With AstraZeneca's Imfinzi For Treatment Of Pancreatic Cancer Demonstrating Signs Of Both No Significant Toxicity And Superior PFS And OS.Company Also Bolstered Cash Position To Fund Operations For ~12 Months
Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both
08-04 21:06
